WeTrials
Recruiting

Combination Targeted and Hormonal treAtMEnt of Low-gradE Serous Ovarian Cancer in the upfroNt Setting

What is this study?

This study is testing a new combination of three medications—avutometinib, defactinib, and letrozole—to see how well they fight a slow-growing type of ovarian cancer. Researchers want to find out if this drug combination is safe and effective as an initial treatment approach.

Who can participate?

You may be able to join if you are a woman aged 18 or older with a confirmed diagnosis of low-grade serous ovarian or peritoneal cancer. This study is mainly for patients where major surgery is not the best first option, or for those who still have some cancer remaining after surgery.

What will happen?

Participants in this study will receive a combination of targeted cancer-fighting medications and a hormone-blocking pill. Your health and the response of your cancer will be closely monitored through regular check-ups and imaging scans.

Where and when?

This study is currently recruiting participants at locations in Atlanta, Georgia, and multiple sites in New Jersey. Your care team can help you determine if a participating location is convenient for you.

Key Points
  • 1Tests a combination of three medications for low-grade serous ovarian cancer.
  • 2Currently looking for participants and is open for recruitment.
  • 3Takes place at medical centers in Georgia and New Jersey.

Related links

Outside pages about this study, checked by our team

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Low-Grade Serous Ovarian Cancer

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.